# New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)

Source: https://onco.cc/terms/new-onset-diabetes-pancreatic-cancer/  
OnCo record `new-onset-diabetes-pancreatic-cancer` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A pancreatic cancer can cause diabetes before any other symptom, so new diabetes after the age of 50, especially with weight loss rather than weight gain, is a recognised warning sign. About one in a hundred such people is found to have pancreatic cancer within three years; a simple score using weight change, blood sugar change and age picks out the smaller group who should have a scan.

## Summary

The link runs both ways. Long-standing type 2 diabetes raises pancreatic cancer risk about 1.8- to 1.9-fold (Huxley 2005; Ben 2011), but the association is strongest in the first years after diabetes is diagnosed (odds ratio 2.1 for diabetes of under four years against 1.5 for five years or more, Huxley 2005), which is the tumour causing the diabetes rather than the reverse. In 512 newly diagnosed patients with pancreatic cancer, 47 percent had diabetes against 7 percent of age-matched controls, much of it new-onset, and it often resolved after the cancer was removed, so the tumour is diabetogenic (Pannala 2008); in a primary care cohort 47 percent of 111 patients had diabetes, 58 percent of it new-onset, and in 80 percent of those the diabetes began while the cancer was asymptomatic, a median of 6.5 months before diagnosis, while about a third of the new diabetes went undiagnosed (Aggarwal 2012). In 2,122 Rochester residents aged 50 or over who first met criteria for diabetes, 18 (0.85 percent, about 1 percent) were diagnosed with pancreatic cancer within three years, several times the expected rate (Chari 2005). One percent is too low to scan everyone, so the ENDPAC score (Enriching New-Onset Diabetes for Pancreatic Cancer) weights change in weight, change in blood glucose and age at onset: a score of 3 or more identified patients who developed cancer within three years with 80 percent sensitivity and specificity in the discovery cohort and 78 percent sensitivity and 85 percent specificity in validation, where cancer prevalence in the high-score group was 3.6 percent (Sharma 2018). NICE NG12 (1.2.5) lists new-onset diabetes with weight loss at 60 or over among the triggers for an urgent direct-access CT, and Cancer Research UK's symptoms page names new diabetes, or diabetes diagnosed within the previous year, as a sign. Cohort studies of new-onset diabetes with blood banking, and the ideas on this site that pair the signal with multi-cancer blood tests or continuous glucose monitoring, are trying to turn the window of about six months into earlier diagnoses. Living with the diabetes once the cancer is diagnosed (type 3c diabetes, its treatment and the diabetes team) is a separate glossary term.

## Fields

- Kind: Term
- Last checked: 2026-09-24
- Also known as: New-onset diabetes and pancreatic cancer; Pancreatic cancer-associated diabetes; ENDPAC score; END-PAC; Enriching New-Onset Diabetes for Pancreatic Cancer; Diabetes with weight loss
- Tags: gi; pancreatic

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pancreatic_cancer
- Chari, Gastroenterology 2005: probability of pancreatic cancer following diabetes, Rochester population: https://doi.org/10.1053/j.gastro.2005.05.007
- Pannala, Gastroenterology 2008: prevalence and profile of pancreatic cancer-associated diabetes: https://doi.org/10.1053/j.gastro.2008.01.039
- Aggarwal, Pancreatology 2012: new-onset diabetes in pancreatic cancer in primary care: https://doi.org/10.1016/j.pan.2012.02.003
- Sharma, Gastroenterology 2018: the ENDPAC model for pancreatic cancer risk in new-onset diabetes: https://doi.org/10.1053/j.gastro.2018.05.023
- Huxley, Br J Cancer 2005: type 2 diabetes and pancreatic cancer, meta-analysis of 36 studies: https://doi.org/10.1038/sj.bjc.6602619
- Ben, Eur J Cancer 2011: diabetes mellitus and pancreatic cancer risk, meta-analysis of 35 cohorts: https://doi.org/10.1016/j.ejca.2011.03.003
- NICE NG12: suspected cancer, recommendations by site (pancreatic cancer 1.2.4 and 1.2.5): https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer
- CRUK: symptoms of pancreatic cancer: https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/symptoms

## Connected records

- ideas: [Blood-based pancreatic cancer detection in new-onset diabetes](https://onco.cc/ideas/idea-mced-new-onset-diabetes/), [New diabetes after 50 plus weight loss triggers a pancreatic cancer check](https://onco.cc/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/)
- cancers: [Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors](https://onco.cc/cancers/ipmn-cystic-precursors/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [High-risk pancreatic surveillance (CAPS / PRECEDE)](https://onco.cc/technologies/pancreatic-surveillance/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- terms: [CA 19-9](https://onco.cc/terms/ca19-9/), [Emergency presentation (route to diagnosis)](https://onco.cc/terms/emergency-presentation/), [Positive predictive value (PPV)](https://onco.cc/terms/ppv/), [Stage shift](https://onco.cc/terms/stage-shift/), [Type 3c diabetes with pancreatic cancer](https://onco.cc/terms/type-3c-diabetes-pancreatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/new-onset-diabetes-pancreatic-cancer.json